Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00069576
Status:
COMPLETED
Last Update Posted:
2019-07-15
First Post:
2003-09-29
Brief Title:
Gestational Diabetes Mellitus Trial GDM
Sponsor:
The George Washington University Biostatistics Center
Organization:
The George Washington University Biostatistics Center
Study Overview
Official Title:
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GDM
Brief Summary:
Gestational diabetes mellitus GDM is a type of diabetes high blood sugar that occurs in pregnant women This study will determine whether treating pregnant women who have mild GDM improves the health of their babies The follow-up study will examine whether factors during the previous pregnancy such as blood sugar during pregnancy are associated with the woman and her childs health 4-9 years later
Detailed Description:
Gestational diabetes mellitus is defined as glucose intolerance of variable severity with onset or first recognition during pregnancy The definition applies regardless of insulin use for treatment or the persistence of the condition after pregnancy and does not exclude the possibility that unrecognized glucose intolerance or overt diabetes may have preceded the pregnancy Pre-existing diabetes substantially contributes to perinatal morbidity and mortality The association of milder forms of gestational diabetes with adverse pregnancy outcomes including morbidities such as macrosomia birth trauma and neonatal hypoglycemia remains questionable While it is likely that maternal glucose intolerances reflect a continuum of risk for adverse outcomes it is not known whether there is a benefit to identification and subsequent treatment of mild glucose intolerance during pregnancy This study will determine whether dietary treatment and insulin as required for mild GDM will reduce the frequency of neonatal morbidity associated with mild glucose intolerance
Participants in this study will receive a 50-gram glucose loading test GLT between 24 and 30 weeks gestation Those with a positive GLT will receive a subsequent 3-hour oral glucose tolerance test OGTT Based upon these test results women will be assigned to 4 groups Women with a positive GLT and abnormal OGTT will be randomly assigned to receive either nutritional counseling and diet therapy Group 1 or no specific treatment Group 2a Women with a positive GLT but normal OGTT will be enrolled in Group 2b for observation Women with a negative GLT will be enrolled in Group 3 and will serve as a control group
Women in Group 1 will receive formal nutritional counseling and will be instructed on the techniques of self blood glucose monitoring Patients will take daily blood glucose measurements and will be seen at weekly study visits The study will evaluate birth outcomes including stillbirth neonatal hypoglycemia neonatal hyperinsulinemia neonatal hyperbilirubinemia and birth trauma
The follow-up study will examine if blood sugar levels and treatments during pregnancy influence the health of the mother and child several years later The study will also examine whether there is a genetic link to the health of the mother and child The study visit will include blood pressure body size measurements blood draw and saliva collection and questions related to the mother and childs health and environment
Participants in this study will receive a 50-gram glucose loading test GLT between 24 and 30 weeks gestation Those with a positive GLT will receive a subsequent 3-hour oral glucose tolerance test OGTT Based upon these test results women will be assigned to 4 groups Women with a positive GLT and abnormal OGTT will be randomly assigned to receive either nutritional counseling and diet therapy Group 1 or no specific treatment Group 2a Women with a positive GLT but normal OGTT will be enrolled in Group 2b for observation Women with a negative GLT will be enrolled in Group 3 and will serve as a control group
Women in Group 1 will receive formal nutritional counseling and will be instructed on the techniques of self blood glucose monitoring Patients will take daily blood glucose measurements and will be seen at weekly study visits The study will evaluate birth outcomes including stillbirth neonatal hypoglycemia neonatal hyperinsulinemia neonatal hyperbilirubinemia and birth trauma
The follow-up study will examine if blood sugar levels and treatments during pregnancy influence the health of the mother and child several years later The study will also examine whether there is a genetic link to the health of the mother and child The study visit will include blood pressure body size measurements blood draw and saliva collection and questions related to the mother and childs health and environment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10HD034136 | NIH | None | httpsreporternihgovquickSearchU10HD034136 |
| U10HD021410 | NIH | None | None |
| U10HD027869 | NIH | None | None |
| U10HD027917 | NIH | None | None |
| U10HD027915 | NIH | None | None |
| U10HD034116 | NIH | None | None |
| U10HD034208 | NIH | None | None |
| U10HD040500 | NIH | None | None |
| U10HD040485 | NIH | None | None |
| U10HD040544 | NIH | None | None |
| U10HD040545 | NIH | None | None |
| U10HD040560 | NIH | None | None |
| U10HD040512 | NIH | None | None |
| U10HD036801 | NIH | None | None |
| U10HD053118 | NIH | None | None |
| U10HD053097 | NIH | None | None |
| U10HD027860 | NIH | None | None |